Eisai, Biogen outline a 30% and 47% advantage for their Alzheimer’s drug BAN2401 — but critics drag stock down

After building sky high expectations over the course of the past few days, Eisai investigators allied with Biogen $BIIB revealed this afternoon that the high dose of their drug BAN2401 produced clearly positive data in a mid-stage study with a statistically significant 30% slowing in the rate of decline compared to the placebo arm in the high dose arm of the study at 18 months.